iRadimed (NASDAQ:IRMD) CEO Sells $356,300.00 in Stock

Key Points

• iRadimed CEO Roger Susi sold 5,000 shares of stock for a total of $356,300, decreasing his ownership by 0.21% to 2,352,500 shares.
• Following the sale, iRadimed's stock price dropped by 1.9%, closing at $70.19, with a 12-month high of $74.43.
• The company recently announced a quarterly dividend of $0.17 per share, resulting in an annualized dividend yield of 1.0% and a payout ratio of 41.98%.

iRadimed Corporation (NASDAQ:IRMD - ) CEO Roger Susi sold 5,000 shares of the business's stock in a transaction dated Tuesday, September 23rd. The stock was sold at an average price of $71.26, for a total transaction of $356,300.00. Following the transaction, the chief executive officer owned 2,352,500 shares in the company, valued at $167,639,150. This represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

iRadimed Stock Down 1.9%

Shares of NASDAQ IRMD traded down $1.38 during midday trading on Wednesday, hitting $70.19. 26,511 shares of the company's stock were exchanged, compared to its average volume of 45,021. The company's 50 day moving average price is $67.83 and its 200 day moving average price is $59.36. iRadimed Corporation has a 12 month low of $46.86 and a 12 month high of $74.43. The firm has a market capitalization of $892.82 million, a PE ratio of 43.33 and a beta of 1.02.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 28th. Stockholders of record on Monday, August 18th were paid a dividend of $0.17 per share. The ex-dividend date was Monday, August 18th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.0%. iRadimed's dividend payout ratio (DPR) is 41.98%.

Hedge Funds Weigh In On iRadimed

Several institutional investors and hedge funds have recently modified their holdings of the business. Jump Financial LLC grew its position in shares of iRadimed by 4.9% during the 1st quarter. Jump Financial LLC now owns 4,300 shares of the medical equipment provider's stock worth $226,000 after purchasing an additional 200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in iRadimed by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,577 shares of the medical equipment provider's stock valued at $252,000 after purchasing an additional 204 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of iRadimed by 78.7% in the first quarter. First Horizon Advisors Inc. now owns 513 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 226 shares during the last quarter. Martingale Asset Management L P increased its position in iRadimed by 2.4% during the 1st quarter. Martingale Asset Management L P now owns 12,831 shares of the medical equipment provider's stock worth $673,000 after purchasing an additional 300 shares in the last quarter. Finally, State of Wyoming boosted its position in iRadimed by 11.3% in the first quarter. State of Wyoming now owns 3,013 shares of the medical equipment provider's stock valued at $158,000 after buying an additional 307 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.